Orthopoxvirus Seroprevalence and Infection Susceptibility in France, Bolivia, Laos, and Mali.
Bolivia
France
Laos
Mali
Orthopoxvirus
cowpox virus
monkeypox virus
seroprevalence
sexually transmitted infections
vaccinia virus
viruses
zoonoses
Journal
Emerging infectious diseases
ISSN: 1080-6059
Titre abrégé: Emerg Infect Dis
Pays: United States
ID NLM: 9508155
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
pubmed:
8
11
2022
medline:
24
11
2022
entrez:
7
11
2022
Statut:
ppublish
Résumé
To determine a demographic overview of orthopoxvirus seroprevalence, we tested blood samples collected during 2003-2019 from France (n = 4,876), Bolivia (n = 601), Laos (n = 657), and Mali (n = 255) for neutralizing antibodies against vaccinia virus. In addition, we tested 4,448 of the 4,876 samples from France for neutralizing antibodies against cowpox virus. We confirmed extensive cross-immunity between the 2 viruses. Seroprevalence of antibodies was <1% in Bolivia, <5% in Laos, and 17.25% in Mali. In France, we found low prevalence of neutralizing antibodies in persons who were unvaccinated and vaccinated for smallpox, suggesting immunosenescence occurred in vaccinated persons, and smallpox vaccination compliance declined before the end of compulsory vaccination. Our results suggest that populations in Europe, Africa, Asia, and South America are susceptible to orthopoxvirus infections, which might have precipitated the emergence of orthopoxvirus infections such as the 2022 spread of monkeypox in Europe.
Identifiants
pubmed: 36343384
doi: 10.3201/eid2812.221136
pmc: PMC9707606
doi:
Substances chimiques
Antibodies, Neutralizing
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2463-2471Références
Nat Med. 2003 Sep;9(9):1131-7
pubmed: 12925846
Vet Microbiol. 2011 Aug 26;152(1-2):29-38
pubmed: 21571451
Am J Trop Med Hyg. 2013 May;88(5):962-970
pubmed: 23458954
Emerg Infect Dis. 2009 May;15(5):781-4
pubmed: 19402968
Clin Diagn Lab Immunol. 2005 Apr;12(4):520-4
pubmed: 15817760
Nat Med. 2005 Jul;11(7):740-7
pubmed: 15951823
Emerg Infect Dis. 2002 Dec;8(12):1495-6
pubmed: 12498670
PLoS Negl Trop Dis. 2019 Oct 16;13(10):e0007791
pubmed: 31618206
Emerg Infect Dis. 2008 Apr;14(4):670-1
pubmed: 18394293
Biodivers Conserv. 2020;29(11-12):3095-3102
pubmed: 32836920
Nat Med. 2001 Dec;7(12):1271-3
pubmed: 11726956
Vet Ital. 2010 Oct-Dec;46(4):439-48
pubmed: 21120799
J Immunol. 2003 Nov 15;171(10):4969-73
pubmed: 14607890
PLoS One. 2013 Apr 16;8(4):e60127
pubmed: 23613718
J Infect Dis. 1990 Mar;161(3):446-8
pubmed: 2155973
Euro Surveill. 2018 Sep;23(38):
pubmed: 30255836
Ann Bretagne Payes Ouest. 1979;86(3):265-76
pubmed: 11631442
Nature. 2010 Dec 2;468(7324):647-52
pubmed: 21124449
Trends Microbiol. 2001 Jan;9(1):15-8
pubmed: 11166237
Indian J Virol. 2013 Dec;24(3):295-305
pubmed: 24426291
Emerg Infect Dis. 2019 Feb;25(2):281-289
pubmed: 30666937
Science. 2001 Nov 2;294(5544):985
pubmed: 11691969
MMWR Morb Mortal Wkly Rep. 2003 Jun 27;52(25):589-90
pubmed: 12836628
Viruses. 2020 May 18;12(5):
pubmed: 32443405
J Clin Virol. 2005 Jan;32(1):47-52
pubmed: 15572006
Indian J Med Res. 1997 Nov;106:441-6
pubmed: 9415737
Bull World Health Organ. 1975;52(3):307-11
pubmed: 1084801
Proc Natl Acad Sci U S A. 2021 Apr 27;118(17):
pubmed: 33820825
N Engl J Med. 2007 Nov 8;357(19):1903-15
pubmed: 17989383
Am J Med. 2008 Dec;121(12):1058-64
pubmed: 19028201
Epidemiol Infect. 2019 Jan;147:e238
pubmed: 31364567
Blood. 2008 May 1;111(9):4653-9
pubmed: 18316630
MMWR Morb Mortal Wkly Rep. 2018 Mar 16;67(10):306-310
pubmed: 29543790
PLoS Negl Trop Dis. 2018 Mar 7;12(3):e0006239
pubmed: 29513667
Euro Surveill. 2001 Nov;6(11):171-8
pubmed: 11891388
J Virol. 1996 Apr;70(4):2627-31
pubmed: 8642697
J Exp Med. 2004 Jun 7;199(11):1585-93
pubmed: 15184506
J Gen Virol. 2005 Nov;86(Pt 11):2955-2960
pubmed: 16227216
PLoS One. 2013;8(2):e55808
pubmed: 23457480
Bull Acad Natl Med. 1955 Oct 4-11;139(25-26):417-20
pubmed: 13284423